Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Go back to Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027| Medtronic Inc. (NYSE: MDT) | Delayed: 79.27 -0.07 (0.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.34 | 52 Week High | $89.27 | |||
| Open | $79.17 | 52 Week Low | $71.03 | |||
| Day High | $79.87 | P/E | 22.52 | |||
| Day Low | $78.30 | EPS | $3.52 | |||
| Volume | 10,018,610 | |||||
| (NASDAQ: OBIO) | Delayed: 4.08 +0.09 (2.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.99 | 52 Week High | $ | |||
| Open | $4.03 | 52 Week Low | $ | |||
| Day High | $4.12 | P/E | N/A | |||
| Day Low | $3.89 | EPS | $ | |||
| Volume | 260,354 | |||||
